Colin Law

Practice Areas

Mr. Law is a partner in Fangda's Hong Kong Office. His practice focuses on capital markets and securities transactions. His experience includes advising Bulge Bracket US Investment Banks and chinese companies on international public offerings, takeovers of public companites, privatization and regulatory matters. He is particularly involved in the healthcare, biotech and media sectors. Colin serves on the Board of Hong Kong biomedical development advisory panel. He has wide experience representing top-notch international financial institutions including Bank of America Merrill Lynch, CITIC Group, Goldman Sachs and Morgan Stanley.

Professional Memberships

Admitted to practice in Hong Kong SAR (1993)

Admitted to practice in England and Wales (1997)

Languages Spoken

-English

-Mandarin Chinese

-Cantonese

Education

Experience

Corporate Finance:

-Advised Apollo Future Mobility (HKEx stock code: 860) to acquire the EU business of WM Motor valued at approximately US$2 billion through a reverse takeover and whitewash, to be followed by a US$450 million placing.

-Acting for CICC and HSBC as sponsors and underwriters counsel for the US$106 million spin-off global offering and initial public offering of Jinmao Property Services Co., Limited (HKEx stock code: 816) on the Main Board of the HKEx.

-JW (Cayman) Therapeutics Co. Ltd, a leading clinical and pre-clinical stage cell therapy company in China, in connection with its US$400 million global offering on the Main Board of the HKEx.

-Represented WuXi Biologics (Cayman) Inc. (HKEx stock code: 2269) and its controlling shareholders in successive primary and secondary placing transactions since the listing on the Main Board of the HKEx, with an aggregate transaction value of over US$12.5 billion.

-Represented Morgan Stanley, Huatai Securities, Goldman Sachs and J.P. Morgan as placing agents in the H-Share placement of WuXi AppTec Co., Ltd. (HKEx stock code: 2359) amounted up to over US$7 billion.

-Represented Jinxin Fertility Group Limited (HKEx stock code: 1951) and its substantial shareholder in successive primary and secondary placing transactions since the listing on the Main Board of the HKEx, with an aggregate transaction value of over US$408 million.

-Jinxin Fertility Group Limited in its US$400 million global offering and initial public offering on the Main Board of the HKEx.

-Morgan Stanley Asia Limited, Huatai Financial Holdings (Hong Kong) Limited and Goldman Sachs (Asia) L.L.C. as sponsors and global coordinators in the US$1 billion global H-share offering of WuXi AppTech Co., Ltd on the Main Board of the HKEx.

-Bank of America Merrill Lynch, Morgan Stanley and China Merchants Securities as sponsors in connection with the approximately US $510 million global offering and initial public offering of WuXi Biologics (Cayman) Inc. on the Main Board of the HKEx.

-Bank of America Merrill Lynch and Goldman Sachs as sponsors for the US $205 million spin-off listing of Frontage, the US subsidiary of TigerMed.

-Bank of America Merrill Lynch as sponsor and Morgan Stanley, Citigroup Global Capital Asia Limited and China International Capital Corporation as global coordinators in connection with its US $200 million global offering of Koolearn Technology Holding Ltd. on the Main Board of the HKEx.

-Citigroup and CCB International Capital Limited as joint sponsors and joint global coordinators in connection with the US $113 million global offering and initial public offering of Zhaoqing Kepei Education Group Limited on the Main Board of the HKEx.

-Goldman Sachs (Asia) L.L.C., CLSA Limited, UBS AG, Hong Kong branch and Guotai Junan Securities (Hong Kong Limited) as underwriters in the HK $900 million global offering of Hua Medicine on the Main Board of The Stock Exchange of Hong Kong Limited, one of the first Chapter 18A IPOs in Hong Kong.

-Jacobson Pharma Corporation Limited, a leading pharmaceutical company in Hong Kong, in its global offering and initial public offering on the Main Board of the HKEx.

-Tianli Education International Holdings Limited in its HK $1.73 billion (US $220 million) global offering and initial public offering on the Main Board of the HKEx.

-Bank of America Merrill Lynch and Morgan Stanley as sponsors in connection with the approximately US $1.15 billion initial public offering (before the exercise of the over-allotment option) of Dali Foods Group Company Limited on the Main Board of the HKEx.

-Citigroup Global Markets Asia Limited, Citigroup Global Markets Limited, CITIC CLSA Capital Markets Limited and CLSA Limited as joint global sponsors, joint global coordinators and joint lead managers in connection with the US $88 million H-share initial public offering of Wenzhou Kangning Hospital Co., Ltd. on the Main Board of the HKEx.

-Morgan Stanley, Goldman Sachs and China International Capital Corporation as the underwriters in connection with the approximately US $248 million primary listing and global offering of IMAX China holding, Inc., a subsidiary of IMAX Corporation, on the Main Board of the HKEx.

-Harmonicare Medical Holdings Limited, a private obstetrics and gynecology hospital group, in connection with its US $205.1 million (HK $1.59 billion) global offering and primary listing on the Main Board of the HKEx.

-CGN Power Co., Ltd., the largest nuclear power producer in China, in connection with its US $3.2 billion (US $3.6 billion upon full exercise of over-allotment option) primary listing on the Main Board of the HKEx and global offering.

-Fu Shou Yuan International Group Limited, a death care services provider in the PRC, in its US $215 million primary listing and global offering of ordinary shares on the Main Board of the HKEx.

-Future Land Development Holdings, a Chinese real estate developer, in connection with the HK $2.06 billion (US $265 million) Hong Kong initial public offering.

-NASDAQ-listed Melco Crown Entertainment Limited for dual primary listing by way of introduction on the Main Board of the HKSE. The sponsors were Credit Suisse and Deutsche Bank.

-GE China in obtaining an exemption from Hong Kong Securities and Futures Commission in relation to documents disclosure requirement of privatization of a public company.

-The underwriters, led by CICC, Goldman Sachs, J.P. Morgan, Morgan Stanley, BOCI and Credit Suisse, in the US $1.7 billion initial public offering, Rule 144A/Regulation S offering and Hong Kong Stock Exchange listing of the H shares of Changsha Zoomlion Heavy Industry Science and Technology Development Co., Ltd., a leading China-based construction machinery company.

-Morgan Stanley and UBS as joint sponsors in the US $850 million initial public offering of shares in Sihuan Pharmaceutical Holdings Group Ltd. on the Main Board of the HKEx.

-Midas Holdings Limited, a Singapore-incorporated company, in its secondary listing on the HKEx. The Company is the leading manufacturer of aluminum alloy extrusion products for the passenger rail transportation sector in China. The deal raised approximately HK $1.17 billion (before exercise of the over-allotment option) by way of a Hong Kong public offering and an international placing.

Mergers and Acquisitions:

-

Regulatory:

-